Monitoring angiogenesis in human melanoma xenograft model using contrast-enhanced ultrasound imaging

Ultrasonic Imaging

Volumn 30, Issue 4, 2008, Pages 237-246

  Forsberg, F ^a   Ro, R J ^a,b   Liu, J B ^a   Lipcan, K J ^a   Potoczek, M ^c   Nazarian, L N ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b DREXEL UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Angiogenesis; Contrast enhanced ultrasound imaging; Melanoma; Murine xenograft model; Pulse inversion harmonic imaging

Indexed keywords

CELL CULTURE; CELL ENGINEERING; DERMATOLOGY; ENDOTHELIAL CELLS; MAMMALS; ONCOLOGY; REGRESSION ANALYSIS; TUMORS; ULTRASONIC IMAGING;

ANGIOGENESIS; CONTRAST ENHANCED ULTRASOUND; MELANOMA; MURINE XENOGRAFT MODEL; PULSE INVERSION HARMONIC IMAGING;

MEDICAL IMAGING;

CD31 ANTIGEN; CYCLOOXYGENASE 2 INHIBITOR; PERFLUTREN; TUMOR MARKER; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER TRANSPLANTATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LINEAR REGRESSION ANALYSIS; MELANOMA; MONITORING; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUDE MOUSE; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

EID: 66749183436     PISSN: 01617346     EISSN: None     Source Type: Journal    
DOI: 10.1177/016173460803000407     Document Type: Article

References (34)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82, 4-6 (1990). (Pubitemid 20020880)
2. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1, 149-153 (1995).
3. Li WW. Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. Acad Radiol 7, 800-811 (2000).
4. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 9, 713-725 (2003). (Pubitemid 36749220)
5. Perini R, Choe R, Yodh AG, et al. Non-invasive assessment of tumor neovasculature: techniques and clinical applications. Cancer Metastasis Rev 27, 615-630 (2008).
6. Folkman J, Hahnfeldt P, Hlatky L. The Logic of Anti-Angiogenic Gene Therapy. Target Tissues and Target Diseases - Cancer (Cold Spring Harbor Laboratory Press, 1998).
7. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 271, 603-606 (1996). (Pubitemid 26034900)
8. Risau W. Mechanisms of angiogenesis. Nature, 386, 671-674 (1997). (Pubitemid 27193480)
9. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Intl 56, 794-814 (1999). (Pubitemid 29411709)
10. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51, 143-158 (2006). (Pubitemid 43144358)
11. Denkert C, Köbel M, Berger S, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 61, 303-308 (2001). (Pubitemid 32095731)
12. Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127, 411-417 (2001). (Pubitemid 32524357)
13. Xu XC. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anti-Cancer Drugs 13, 127-137 (2002).
14. Newman PJ. The biology of PECAM-1. J Clin Invest 99, 3-8 (1997). (Pubitemid 27058286)
15. O'Brien CD, Gaoyuan C, Makrigiannakis A, De Lisser HM. Role of immunoreceptor tyrosine-based inhibitory motifs of PECAM-1 in PECAM-1-dependent cell migration. Am J Physiol Cell Physiol 287, C1103-C1113 (2004). (Pubitemid 39238335)
16. th, 2009).
17. Ferrara KF, Merritt CRB, Burns PN, et al. Evaluation of tumor angiogenesis with US: imaging, Doppler and contrast agents. Acad Radiol 7, 824-839 (2000).
18. Neeman M, Gilad AA, Dafni H, Cohen B. Molecular imaging of angiogenesis. J Magn Reson Imaging 25, 1-12 (2007). (Pubitemid 46095196)
19. Goldberg BB, Raichlen JS, Forsberg F. Ultrasound Contrast Agents: Basic Principles and Clinical Applications, 2nd Ed. (Martin Dunitz Ltd., London, 2001).
20. Forsberg F, Ro R, Potoczek M, et al. Assessment of angiogenesis: implications for ultrasound imaging. Ultrasonics 42, 325-330 (2004).
21. Forsberg F, Kuruvilla B, Pascua MB, et al. Comparing contrast-enhanced color flow imaging and pathological measures of breast lesion vascularity. Ultrasound Med Biol 34, 1365-2137 (2008).
22. Wahl ML, Owen JA, Burd R, et al. Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Canc Ther 1, 617-628 (2002).
23. Forsberg F, Dicker AP, Thakur ML, et al. Comparing contrast enhanced ultrasound to immunohistochemical markers of angiogenesis in a human melanoma xenograft model: preliminary results. Ultrasound Med Biol 28, 445-451, 2002. (Pubitemid 34603764)
24. Shi WT, Forsberg F. Ultrasonic characterization of the nonlinear properties of contrast microbubbles. Ultrasound Med. Biol 26, 93-104 (2000). (Pubitemid 30045527)
25. Bell DS, Bamber JC, Eckersley RJ. Segmentation and analysis of colour Doppler images of tumour vasculature. Ultrasound Med Biol 21, 635-637 (1995).
26. Chaudhari MH, Forsberg F, Voodarla A, et al. Breast tumor vascularity identified by contrast enhanced ultrasound and pathology: initial results. Ultrasonics 38, 105-109 (2000). (Pubitemid 30592600)
27. Fleicher AC. Sonographic depiction of tumor vascularity and flow from in vivo models to clinical applications. J Ultrasound Med 19, 55-61 (2000).
28. Schroeder RJ, Hauff P, Bartels T, et al. Tumor vascularization in experimental melanomas: correlation between unenhanced and contrast enhanced power Doppler imaging and histological grading. Ultrasound Med Biol 27, 761-771 (2001). (Pubitemid 32564875)
29. Iordanescu I, Becker C, Zetter B, Dunning P, Taylor GA. Tumor vascularity: evaluation in a murine model with contrast-enhanced color Doppler US - effect of angiogenesis inhibitors. Radiology, 222, 460-467 (2002). (Pubitemid 34106120)
30. Krix M, Kiessling F, Vosseler S, et al. Comparison of intermittent-bolus contrast imaging with conventional power Doppler sonography: quantification of tumor perfusion in small animals. Ultrasound Med Biol 29, 1093-1103 (2003). (Pubitemid 37020905)
31. Ro RJ, Forsberg F, Liu JB, et al. Contrast enhanced US for monitoring the effect of VEGF Trap on melanoma tumor vascularity. in Proc IEEE Ultrason Symp, pp. 1977-1980 (2007).
32. Niermann KJ, Fleischer AC, Huamani J, et al. Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. J Ultrasound Med 26, 749-756 (2007). (Pubitemid 46870342)
33. Pollard RE, Broumas AR, Wisner ER, Vekich SV, Ferrara KW. Quantitative contrast enhanced ultrasound and CT assessment of tumor response to antiangiogenic therapy in rats. Ultrasound Med Biol 33, 235-245 (2007). (Pubitemid 46240595)
34. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 271, 58-65 (1994).